首页> 外文期刊>Resuscitation. >Percutaneous left ventricular assistance in post cardiac arrest shock: Comparison of intra aortic blood pump and IMPELLA Recover LP2.5
【24h】

Percutaneous left ventricular assistance in post cardiac arrest shock: Comparison of intra aortic blood pump and IMPELLA Recover LP2.5

机译:经皮左心室辅助治疗心脏骤停后休克:主动脉内血泵和IMPELLA Recover LP2.5的比较

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aim: To compare the feasibility, safety and outcome of IMPELLA Recover LP2.5 cardiac assistance and intra aortic balloon pump (IABP) in patients with post-cardiac arrest shock. Background: The high early mortality rate of post-cardiac arrest patients is attributed to a "post cardiac arrest syndrome" characterized by an acute and transient left ventricular (LV) systolic dysfunction. LV assistance with IMPELLA Recover LP2.5 is proposed in most severe patients. Methods: Retrospective single center registry from January 2007 to October 2010. All survivors of out-of-hospital cardiac arrest with patent or predictive factors for the occurrence of post-resuscitation shock assisted by either IMPELLA or intra aortic balloon pump (IABP) device immediately after the coronary angiogram were included. Results: 78 post-cardiac arrest patients were assisted by one of the devices (35 by IMPELLA and 43 by IABP). Median "no flow" and median "low flow" were similar at admission as were hemodynamic parameters. The feasibility of IMPELLA implantation was good (97%). At 28 days, the survival rate without sequellae was 23.0% in the IMPELLA and 29.5% in the IABP group (p= 0.61). Vascular complications were observed equally in both groups (3 vs 2, p= 0.9). Serious bleeding complications occurred in 26% of IMPELLA patients vs 9% of IABP patients (p= 0.06). Conclusion: Early LV assistance by the IMPELLA LP2.5 is feasible in patients with post-resuscitation shock. The rate of complications did not differ substantially in the two groups, except for a trend toward a higher rate of bleeding events with IMPELLA. These encouraging findings must be confirmed in a larger clinical study.
机译:目的:比较IMPELLA Recover LP2.5心脏辅助和主动脉内球囊泵(IABP)在心脏骤停后休克患者中的可行性,安全性和结果。背景:心脏骤停后患者的高早期死亡率归因于“心脏骤停后综合征”,其特征是急性和短暂性左心室(LV)收缩功能异常。在大多数重症患者中建议使用IMPELLA Recover LP2.5进行LV辅助。方法:2007年1月至2010年10月的单中心回顾性研究。所有院外心脏骤停的幸存者均需借助IMPELLA或主动脉内球囊泵(IABP)装置辅助进行复苏后休克发生的专利或预测因素包括冠状动脉造影后。结果:78例心脏骤停后患者在其中一种设备(35例由IMPELLA和43例由IABP)协助。入院时中位“无血流”和中位“低血流”与血流动力学参数相似。 IMPELLA植入的可行性很好(97%)。在28天时,无后遗症的存活率在IMPELLA组为23.0%,在IABP组为29.5%(p = 0.61)。在两组中平均观察到血管并发症(3 vs 2,p = 0.9)。 IMPELLA患者中发生严重出血并发症的比例为26%,而IABP患者中为9%(p = 0.06)。结论:IMPELLA LP2.5的早期LV辅助在复苏后休克患者中是可行的。两组的并发症发生率没有显着差异,只是IMPELLA的出血事件发生率呈上升趋势。这些令人鼓舞的发现必须在更大的临床研究中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号